Trial
NCT01832896
Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
NYU Langone Health
Collaborators
Dyax Corp.
Condition
Hereditary Angioedema Types I and II
Intervention
Ecallantide subcutaneous dosing
Why stopped
PI indicated departure from institution, inability to complete study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-31